Orgenesis inks co-development agreement with Accellix to improve quality control in its cellular therapy system – Proactive Investors USA & Canada

The agreement allows the company to integrate Accellixs proprietary sampling and analysis technology into its Point-of-Care platform

Inc (), a cell and gene therapy company, has signed a co-development agreement with cell analytics company Accellix Inc.

The agreement allows Orgenesis to integrate Accellixs proprietary sampling and analysis technology its optic system, cartridges, reagents and software into the companys Point-of-Care (POCare) cellular therapy platform.

POCare works by collecting, processing and supplying cells for various therapeutic treatments. The idea is to shrink the cost of cell and gene therapy through automation. By integrating Accellixs technology, Orgenesis can greatly improve its quality control.

By partnering with Accellix and integrating its advanced optic technologies, cartridges and software, we believe that this will advance Orgenesis processing capabilities for different types of cells for our POCare services and platform, Orgenesis CEO Vered Caplan said.

We believe the Orgenesis POCare platform can deliver a transformative option to the cell and gene therapy market that will lower costs in order to potentially bring our autologous therapies to patients in a cost effective, high quality and scalable manner.

Orgenesis is a biotechnology company based in Germantown, Maryland. In addition to POCare, it also owns a subsidiary, Masthercell Global, which operates a Contract Development and Manufacturing Organization platform, which provides manufacturing and development services for biopharmaceutical companies.

Contact Andrew Kessel at [emailprotected]

Follow him on Twitter @andrew_kessel

See more here:
Orgenesis inks co-development agreement with Accellix to improve quality control in its cellular therapy system - Proactive Investors USA & Canada